The role of novel anticoagulants in the management of venous thromboembolism

Skeik, Nedaa; Murphy, Caleb J.; Porten, Brandon R

doi:10.1177/1358863x14534309

Cited by 7 publications

(16 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, a number of sustained release systems for hirudin have been reported in the literature, such as the PEG-hirudin 17 , dextran coupled hirudin 18 , hydrogel based hirudin 19 and cationic liposome delivery system 20 . However, they all suffer from undesired long anticoagulation time that often leads to the increased risk of bleeding, which makes them unsuitable to treat patients 21 . In contrast, peptide S2 exhibited an improved half-life (T 1/2 = 212.2 ± 58.4 min) that is comparable to small molecule drugs such as argatraban 22 and dabigatran (Pradaxa) 23 .…”

Section: Discussionmentioning

confidence: 99%

A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity

Liu¹,

Yu²,

Huang³

et al. 2015

Sci Rep

View full text Add to dashboard Cite

A novel hirudin isoform 3 mimetic peptide, named peptide S2, has been prepared by introduction of a stearic acid modification. Peptide S2 exhibited superior inhibitory activity to hirulog-1 (Bivariludin) and showed significantly higher anticoagulant potency in vivo. Peptide S2 elevated the thrombin time, prothrombin time and activated partial thromboplastin time of rat and human plasma more efficiently than hirulog-1 and the unmodified form of peptide S2 (peptide 1). Furthermore, peptide S2 inhibited arterial thrombosis and inferior vena cava in rat model 8 h after administration, and was 10-fold more potent than hirulog-1 300 min after administration of 0.1 μmol/kg peptide. The enhanced antithrombotic activity could be attributed to its long half-life (T1/2 = 212.2 ± 58.4 min), which was 13.1 and 14.7-fold longer than those of hirulog-1 (T1/2 = 15.1 ± 1.3 min) and peptide 1 (T1/2 = 13.5 ± 2.6 min), respectively. Further enzymatic degradation and binding assay with human serum albumin (HSA) demonstrated that the longer duration time should be originated from the slowing of trypsin or thrombin–mediated degradation, as well as its binding to HSA. The improved pharmacokinetic properties observed for peptide S2 has made it a promising therapeutic agent for the treatment of thrombi-related diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity

Liu¹,

Yu²,

Huang³

et al. 2015

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Use of heparin followed by vitamin K antagonists (VKAs) remained unchanged irrespective of the presence of aPL, and LAC may be false-positive due to the anticoagulant treatment. It is now suggested to use rivaroxaban in thrombotic APS [14] and many studies reported that the efficacy and safety had same benefits with traditional anticoagulation therapy [15]. There is no study reporting that Rivaroxaban is a leading factor of the APS, although no antidotes to reverse Rivaroxaban have been reported as well [16].…”

Section: Discussionmentioning

confidence: 99%

Bilateral adrenal hemorrhage in APLS (anti-phospholipid syndrome) patient on Novel Anticoagulant: a case report

Bakhsh¹,

Alkhathami²,

Mukaddam³

et al. 2017

EJMCR

View full text Add to dashboard Cite

show abstract

“…Treatment is initiated in the acute setting and typically continued for at least 6 months following the diagnosis of DVT. Traditional therapy has involved the use of low-molecular-weight heparin bridged to warfarin, but new anticoagulants such as factor Xa (eg, apixaban and rivaroxaban) and direct thrombin inhibitors (eg, dabigatran) are effective for acute and chronic applications (12). The major limitation of anticoagulation as an isolated therapy for acute DVT is its lack of a thrombolytic effect, which limits the speed and extent of venous recanalization for large clots and, in turn, leads to prolongation of acute symptoms, more severe venous valvular damage,…”

Section: Treatment Modalities Systemic Anticoagulationmentioning

confidence: 99%

Role of Catheter-directed Thrombolysis in Management of Iliofemoral Deep Venous Thrombosis

Chen¹,

Sudheendra²,

Stavropoulos³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

The treatment for iliofemoral deep venous thrombosis (DVT) is challenging, as the use of anticoagulation alone can be insufficient for restoring venous patency and thus lead to prolongation of acute symptoms and an increased risk of chronic complications, including venous insufficiency and postthrombotic syndrome (PTS). In these cases, earlier and more complete thrombus removal can ameliorate acute symptoms and reduce long-term sequelae. Endovascular therapies involving the use of pharmacologic, mechanical, and combined pharmacomechanical modalities have been developed to achieve these goals. The most frequently used of these techniques, catheter-directed thrombolysis (CDT), involves the infusion of a thrombolytic agent through a multiple-side-hole catheter placed within the thrombosed vein to achieve high local doses and thereby break down the clot while minimizing systemic thrombolytic agent exposure. Randomized controlled trial results have indicated decreased PTS rates and improved venous patency rates in patients treated with CDT compared with these rates in patients treated with anticoagulation. The use of newer pharmacomechanical techniques, as compared with conventional CDT, reduces procedural times and thrombolytic agent doses and is the subject of ongoing investigations. Endovascular thrombus removal techniques offer a means to improve venous valvular function and decrease the risk of debilitating long-term complications such as PTS and are a promising option for treating patients with iliofemoral DVT. (©)RSNA, 2016.

show abstract

The role of novel anticoagulants in the management of venous thromboembolism

Cited by 7 publications

References 66 publications

A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity

A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity

Bilateral adrenal hemorrhage in APLS (anti-phospholipid syndrome) patient on Novel Anticoagulant: a case report

Role of Catheter-directed Thrombolysis in Management of Iliofemoral Deep Venous Thrombosis

Contact Info

Product

Resources

About